Skip to main content

Market Overview

Aurinia Pharma Merits Speculative Buy On M&A Appeal; Phase 3 Study Remains Paramount

Aurinia Pharma Merits Speculative Buy On M&A Appeal; Phase 3 Study Remains Paramount

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s Voclosporin is about to begin Phase 3 trials for first-line treatment of lupus nephritis. The company could be an “ideal acquisition candidate once Phase 3 kicks off,” Mackie Research Capital’s André Uddin said in a report.

Uddin initiated coverage of Aurinia Pharma with a Speculative Buy rating and a 12-month price target of $8. He commented, “Based on the clinical data, market potential of Voclosporin, lack of late-stage competitors and the historical track record of management – we believe Aurinia has the potential to be acquired.”

Team Has M&A Experience

Aurinia Pharma CEO Charlie Rowland has extensive M&A experience. Prior to being co-CEO and chief financial officer of Endo International plc - Ordinary Shares (NASDAQ: ENDP), Rowland was the CFO of Shire Viropharma Inc (NASDAQ: VPHM) when it was acquired by Shire PLC (NASDAQ: SHPG) for $4.2 billion in 2013.

Several members of Aurinia Pharma’s management team, including chairman Richard Glickman, were at Aspreva Pharmaceuticals, which was acquired by Galenica for $915 million in 2007.

“While at Aspreva, this team ran the largest and most important lupus nephritis (LN) trial ever conducted, called the Aspreva Lupus Management Study ("ALMS"), which resulted in the emergence of CellCept (mycophenolate mofetil) as a key treatment for lupus nephritis,” Uddin wrote.

Aurinia Pharma witnessed large growth in short interest in October, according to The Cerbat Gem. Earlier in September, the company had announced positive top-line results from the Phase 2b clinical study of Voclosporin.

Latest Ratings for AUPH

Jan 2021SVB LeerinkMaintainsOutperform
Jan 2021HC Wainwright & Co.MaintainsBuy
Nov 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for AUPH
View the Latest Analyst Ratings


Related Articles (AUPH)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas M&A Initiation Analyst Ratings Trading Ideas General Best of Benzinga

Latest Ratings

FIBKStephens & Co.Downgrades
LEAFCanaccord GenuityDowngrades8.5
AGMSidoti & Co.Downgrades115.0
KEXGabelli & Co.Downgrades
OCGNCantor FitzgeraldDowngrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at